We developed a highly competitive CYP2E1 inhibitor 12-imidazolyl-1-dodecanol (I-ol) (Table S1) and have already demonstrated proof-of-concept that it can successfully be used to treat ASH (Figure S1) and NASH (Figure S2). Here, CYP2E1 is linked to metabolic dysfunction-associated steatohepatitis.